Of late, pharmaceutical behemoth Pfizer Inc.’s PFE stock has struggled, but it remains a bargain with generous dividends. Its ...

The Department of Justice (DoJ) claims that Biohaven – before being acquired by Pfizer – paid "improper remuneration" to some Nurtec ODT (rimegepant) prescribers in the form of speaker fees ...

Biohaven reportedly paid “kickbacks to health care providers to induce prescriptions” of Biohaven’s drug Nurtec ODT. Pfizer, as a result of the action, has agreed to pay $59,746,277 to ...

The drugmaker has revamped how it packages, promotes and sells certain medicines in an effort to overcome a postpandemic ...

Nurtec ODT (rimegepant) is a prescription drug that treats and helps prevent migraine episodes. It works by blocking a certain protein in the brain and nervous system that can cause migraine.

Pfizer's stock has recently struggled but remains a bargain with generous dividends. Is now a good time to invest in PFE?

After learning doctors weren’t prescrbing its migraine drug Nurtec because they assumed insurance coverage would be a hassle, the company ...

Analysts on Wall Street project that Pfizer (PFE) will announce quarterly ... Revenue- Primary Care- Nurtec ODT/Vydura- Worldwide' should come in at $384.55 million. The estimate suggests a ...

Pfizer reported fourth-quarter 2024 adjusted ... Newly acquired product Nurtec ODT/Vydura contributed $392 million in the quarter, which rose 39% year over year, driven by strong demand in the ...